Drug Trial Radar · NCT03955445
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
225
Planned (sponsor's estimate)
Start
Oct 3, 2019
Primary completion
May 30, 2036
Study completion May 30, 2036
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis
Conditions
- C3 Glomerulopathy
- Immune-complex-membranoproliferative Glomerulonephritis
Interventions
LNP023Drug
LNP023 capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- CLNP023X2202 Cohort A-native C3G: Number of participants who achieve the composite renal endpointTime frame: 9-month visit
- CLNP023X2202 Cohort B - kidney transplant and recurrent C3G: Change from baseline in the C3 Deposit ScoreTime frame: 6 - to 9- month visit
- Number of AEs of special interest for participants from CLNP023X2202, CLNP023B12301 and CLNP023B12302Time frame: Participants are expected to continue on study for a minimum of 60 months and a maximum of 84 months
- Number of participants with study drug discontinuation due to an AE (or any safety issue) for participants from CLNP023X2202, CLNP023B12301 and CLNP023B12302Time frame: Participants are expected to continue on study for a minimum of 60 months and a maximum of 84 months
- Number of participants with abnormal clinically significant vital signs,ECGs, and safety laboratory measurements for participants from CLNP023X2202, CLNP023B12301 and CLNP023B12302Time frame: Participants are expected to continue on study for a minimum of 60 months and a maximum of 84 months
Locations
53 sites in 17 countries. Site status is shown where the registry gives one.
Childrens Hospital Colorado
Aurora, Colorado · Recruiting
Georgia Nephrology Research Inst
Lawrenceville, Georgia · Recruiting
University of Iowa Health Care
Iowa City, Iowa · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
Col Uni Med Center New York Presby
New York, New York · Recruiting
Novartis Investigative Site
Buenos Aires, Argentina · Recruiting
Novartis Investigative Site
CABA, Buenos Aires, Argentina · Recruiting
Novartis Investigative Site
Salvador, Brazil · Recruiting
Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil · Recruiting
Novartis Investigative Site
Recife, Pernambuco, Brazil · Recruiting
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Novartis Investigative Site
Botucatu, São Paulo, Brazil · Recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Recruiting
Novartis Investigative Site
Toronto, Ontario, Canada · Active not recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Shanghai, China · Recruiting
Novartis Investigative Site
Prague, Czechia · Active not recruiting
Novartis Investigative Site
Montpellier, France · Recruiting
Novartis Investigative Site
Paris, France · Active not recruiting
Novartis Investigative Site
Paris, France · Recruiting
Novartis Investigative Site
Toulouse, France · Recruiting
Novartis Investigative Site
Erlangen, Germany · Active not recruiting
Novartis Investigative Site
Essen, Germany · Recruiting
Novartis Investigative Site
Hamburg, Germany · Active not recruiting
Novartis Investigative Site
Heidelberg, Germany · Recruiting
Novartis Investigative Site
Mainz, Germany · Recruiting
Novartis Investigative Site
Heraklion Crete., Greece · Active not recruiting
Novartis Investigative Site
Thessaloniki, Greece · Active not recruiting
Novartis Investigative Site
Petah Tikva, Israel · Recruiting
Novartis Investigative Site
Petah Tikva, Israel · Active not recruiting
Novartis Investigative Site
Bari, BA, Italy · Recruiting
Novartis Investigative Site
Ranica, BG, Italy · Recruiting
Novartis Investigative Site
Roma, RM, Italy · Recruiting
Novartis Investigative Site
Niigata, Japan · Active not recruiting
Novartis Investigative Site
Nagoya, Aichi-ken, Japan · Active not recruiting
Novartis Investigative Site
Asahikawa, Hokkaido, Japan · Active not recruiting
Novartis Investigative Site
Sapporo, Hokkaido, Japan · Completed
Novartis Investigative Site
Takatsuki, Osaka, Japan · Active not recruiting
Novartis Investigative Site
Ohtsu, Shiga, Japan · Recruiting
Novartis Investigative Site
Hachiōji, Tokyo, Japan · Recruiting
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.